New subcutaneous formulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) shows positive results for the treatment of active Crohn’s disease in data presented at Digestive Disease Week® 2018
Celltrion Healthcare today presented new research at Digestive Disease Week® (DDW) 2018, that shows the efficacy and safety of the CT-P13 subcutaneous (SC) formulation is comparable to the CT-P13 intravenous (IV) formulation up to week 30 in patients with active Crohn’s disease (CD). The results demonstrate the potential of CT-P13 SC to enhance the treatment options available for patients treated with infliximab.1
The open- label, randomised, controlled, phase I study aimed to find the optimal dose of CT-P13 SC by establishing pharmacokinetic (PK) comparability to CT-P13 IV dosing. The study also evaluated the efficacy and safety of CT-P13 SC over the first 30 weeks in patients with active CD compared to that of CT-P13 IV. 1
Patients with active CD were randomly assigned into four cohorts for the study; one group receiving CT-P13 IV (5mg/kg, Weeks 6, 14, 22 and 30) and the other three receiving different bi-weekly doses of CT-P13 SC (120mg/180mg/240mg). The 30-week results from the study showed comparable efficacy of CT-P13 SC to CT-P13 IV with a similar rate of clinical remissions and changes from baseline of CDAI, CDAI-70 and CDAI-100 scores - standardised disease improvement measurements used to quantify the symptoms of active CD. The safety profiles observed for CT-P13 SC after randomisation were also comparable to CT-P13 IV. Pharmacokinetics and pharmacodynamics modelling on the results suggested a similar dosing of CT-P13 SC to CT-P13 IV in active CD. 1
Mr Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare said, “Together with CT-P13 IV, CT-P13 SC marks a significant milestone for Celltrion Healthcare and our partners. This kind of innovation will enable us to differentiate our portfolio and provide a more convenient and accessible treatment administration option to patients with chronic conditions like IBD in the United States.”
Improving Patient Access in the United States
Up to 3 million people in the United States are affected by IBD, which includes CD and ulcerative colitis (UC)2. Many biologic products have improved the outcomes of patients with IBD, but the costs can substantially burden healthcare systems.
President Donald J. Trump’s recent blueprint includes new actions and proposals to drive down drug prices for all Americans, one being to advance biosimilars to boost price competition and drive reductions in price which will have a significant impact on increasing patient access to effective treatments.
Dr Edmund Pezalla, Former Vice President, Aetna, U.S., said, “The efficient and effective management of inflammatory bowel disease is crucial to patients’ long-term well-being. Biosimilars could offer patients and physicians increased access to a high-quality, lower-cost therapeutic alternative. It is critical to increase education and adopt policies that support the entrance of biosimilars so that patients can have better access to these safe, effective and more cost-efficient medicines in the U.S.”
Notes to editors:
About inflammatory bowel disease
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disabling gastrointestinal disorders that impact every aspect of a patient’s life3. They affect an estimated 5 million people globally4; CD affects about three people per 1,000 and UC about 5 people per 1,000.2
IBD accounts for substantial costs to the healthcare system and society; the direct healthcare costs of IBD is estimated to be €4.6-5.6 billion per year.5
About CT-P13 (biosimilar infliximab)
CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including rheumatoid arthritis and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major European countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 87 countries (as of May 2018) including the US, Canada, Japan and throughout Europe.
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: http://www.celltrionhealthcare.com/
About Digestive Disease Week
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place June 2-5, 2018, at Walter E. Washington Convention Center. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
1 Schreiber S, et al. Novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: Initial results from a phase I open-label randomized controlled trial in patients with active Crohn’s disease. Presentation number Tu2018. Digestive Disease Week (DDW) 2018.
2 Centers for Disease Control and Prevention. Inflammatory Bowel Disease Prevalence (IBD) in the United States. Available at: https://www.cdc.gov/ibd/data-statistics.htm.
3 Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142(1)46–54.
4 The European Federation of Crohn’s & Ulcerative Colitis Associations. What is IBD? Science. Available at: http://www.efcca.org/en/science.
5 Burisch J, et al. The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis (2013)7,322-337.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 17:30:00 | Tiedote
Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented
Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 16:42:00 | Tiedote
Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is
Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 16:30:00 | Tiedote
Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of
Lenovo Data Center Group Delivers Broad Edge Computing Portfolio, Expands Investments in IoT22.2.2019 16:13:00 | Tiedote
Next week at MWC Barcelona, Lenovo Data Center Group (DCG) will showcase continued investments in its solutions supporting IoT and edge computing as part of its IoT growth plan over the next few years. Building on the momentum of its fifth consecutive quarter of profit growth, Lenovo DCG is building a portfolio that takes infrastructure to where the data is, whether that be in the traditional data center, in the cloud or increasingly, at the edge. Today, around 10 percent of enterprise-generated data is created and processed outside a traditional centralized data center or cloud. By 2022, Gartner predicts this figure will reach 75 percent. This migration is driving increased concerns around data privacy, security and regulations coupled with challenges of latency, bandwidth and downtime. Lenovo is addressing these challenges by creating a broad portfolio of edge computing offerings that address the different ways that customers want to deploy edge computing solutions for IoT use cases.
Entrust Datacard to Acquire Market-Leading General Purpose Hardware Security Module Business from Thales22.2.2019 12:47:00 | Tiedote
Entrust Datacard, a leading provider of trusted identity and secure issuance technology solutions, today announced that the company has signed a definitive agreement to acquire Thales’s market-leading General Purpose Hardware Security Module (GP HSM) business, nCipher Security, which has been operating as a separate stand-alone business within Thales since January 2019. Thales is divesting its nCipher GP HSM business, in accordance with Regulatory Clearances necessary to complete Thales’s forthcoming and previously-announced acquisition of Gemalto and to ensure a strong competitive market leader in the HSM market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005135/en/ General Purpose HSMs are a core component of Entrust Datacard’s solutions and are an underlying part of the security infrastructure of the company’s public key infrastructure (PKI) and secure socket layer (SSL) offerings. The acquisition will allow the
Turkcell and US RAN Vendor Airspan Are Laying the Foundation for 5G with an Ultra-Dense AirDensity Network to Support Turkey’s Digital Transformation22.2.2019 12:06:00 | Tiedote
Turkcell and Airspan announce the first deployment of AirDensity to deliver coverage and capacity to the most constrained indoor locations in Turkey as well as extending coverage to rural areas and enabling development of next generation solutions including Drone-based flying cells. AirDensity is based on the multi-award-winning AirUnity platform and part of the Airspan network densification portfolio that counts approximately half a million 4G cells deployed world-wide. This is further proof of the progress of the Feb 23, 2017 strategic cooperation announcement between Turkcell and Airspan. Airspan supports the ‘Made in Turkey’ 5G consortium with an R&D center in the Istanbul Technopark and provides regional support for Airspan’s deployments. Turkcell is deploying AirDensity is the innovative all-wireless small cell to deliver world class user experience to its residential and enterprise customers, develop innovative vertical applications and remain Turkey’s leading digital operator.
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme